Seegene and UK Health Security Agency convene a summit to collectively realize 'a World Free from All Diseases'
April 09, 2024 at 01:54 pm EDT
Share
Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, announced today that Prof. Dame Jenny Harries, Chief Executive of the UK Health Security Agency (UKHSA), visited its headquarters located in Seoul Korea, on March 27.
According to the company, Prof. Harries and her delegation engaged in discussions with Dr. Jong-Yoon Chun, Seegene's founder & CEO, and the management team, in which she expressed strong alignment in collectively moving to realize Seegene's vision of 'a world free from all diseases.'
Prof. Harries expressed keen interest in Seegene's SG OneSystemTM business, the company's technology sharing initiative, as well as its advancements in automated diagnostic reagent development system driven by artificial intelligence (AI) and innovative digital solutions that integrate biotechnology (BT) and information technology (IT).
Highlighting Seegene's rapid response to the Covid-19 pandemic, Prof. Harries commended the company's agility in developing diagnostic reagents within just three weeks and distributing them globally. 'We strongly believe that the speed of testing must be faster than the speed of transmission' explained Dr. Chun, reflecting on the challenges during the pandemic. 'We took swift action by utilizing emergency approvals from governments worldwide and leveraging the global distribution network we had secured prior to the pandemic.'
Seegene has facilitated the rapid and effective isolation of individuals infected with COVID-19 by delivering approximately 350 million diagnostic tests to over 100 countries.
'We greatly value the visit of UKHSA, a world-leading health security agency, to Seegene,' said Dr. Chun. 'We will continue to explore ways for contributing to the cooperation between Korea and the UK, including through our SG OneSystemTM business' he added.
SG OneSystemTM business, or Seegene's technology sharing initiative, is a global strategy aimed at eradicating diseases. It involves sharing the company's syndromic quantitative PCR technology and Seegene's Digitalized Development System (SGDDS) with leading companies worldwide. The initiative enables scientists across the globe to contribute directly to the development of locally tailored diagnostic reagents for various diseases affecting humans, animals, and plants.
To effectively advance this endeavor, Seegene has forged strategic collaborations with industry and academic leaders including Microsoft and Springer Nature, underscoring its commitment to advancing global health solutions through the enhancement of its technology sharing initiative.
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
SEEGENE, INC. 
